Armand JP - Search Results

1

A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11.

Gonçalves E, de Costa L, Abigerges D, Armand JP. Gonçalves E, et al. Among authors: armand jp. J Clin Oncol. 1995 Aug;13(8):2144-6. doi: 10.1200/JCO.1995.13.8.2144. J Clin Oncol. 1995. PMID: 7636561 No abstract available.

2

CPT-11-induced cholinergic effects in cancer patients.

Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A, Herait P. Gandia D, et al. Among authors: armand jp. J Clin Oncol. 1993 Jan;11(1):196-7. doi: 10.1200/JCO.1993.11.1.196. J Clin Oncol. 1993. PMID: 8418235 No abstract available.

3

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.

Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M. Armand JP, et al. Ann Oncol. 1996 Oct;7(8):837-42. doi: 10.1093/oxfordjournals.annonc.a010763. Ann Oncol. 1996. PMID: 8922198 Free article. Clinical Trial.

4

High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.

Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc E, Marty M, Hérait P, Mahjoubi M, Armand JP. Merrouche Y, et al. Among authors: armand jp. J Clin Oncol. 1997 Mar;15(3):1080-6. doi: 10.1200/JCO.1997.15.3.1080. J Clin Oncol. 1997. PMID: 9060548 Clinical Trial.

5

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D. Abigerges D, et al. Among authors: armand jp. J Clin Oncol. 1995 Jan;13(1):210-21. doi: 10.1200/JCO.1995.13.1.210. J Clin Oncol. 1995. PMID: 7799022 Clinical Trial.

6

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D. Abigerges D, et al. Among authors: armand jp. J Natl Cancer Inst. 1994 Mar 16;86(6):446-9. doi: 10.1093/jnci/86.6.446. J Natl Cancer Inst. 1994. PMID: 8120919 Clinical Trial.

7

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M. Chabot GG, et al. Among authors: armand jp. J Clin Oncol. 1996 Jul;14(7):2020-30. doi: 10.1200/JCO.1996.14.7.2020. J Clin Oncol. 1996. PMID: 8683232 Clinical Trial.

8

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al. Chabot GG, et al. Among authors: armand jp. Ann Oncol. 1995 Feb;6(2):141-51. doi: 10.1093/oxfordjournals.annonc.a059109. Ann Oncol. 1995. PMID: 7786822 Free article. Clinical Trial.

9

CPT-11 (irinotecan) in the treatment of colorectal cancer.

Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P. Armand JP, et al. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1283-7. doi: 10.1016/0959-8049(95)00212-2. Eur J Cancer. 1995. PMID: 7577037 Review.

10

[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].

Couteau C, Yakendji K, Terret C, Goncalves E, Armand JP. Couteau C, et al. Among authors: armand jp. Bull Cancer. 1996 Jan;83(1):3-10. Bull Cancer. 1996. PMID: 8672854 Clinical Trial. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

285 results

Search Page

Filters